Mental Health Clinics in Newton Center, MA Accepting Medicare
6 Mental Health Clinics found. Showing 1 - 6
 Kathleen Nardella And Associates Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 1280 Centre St Ste 220, Newton Center, MA 02459 Phone: 301-775-5373 |
Datta Consultants Llc Psychiatry & Neurology - Addiction Medicine Medicare: Medicare Enrolled Practice Location: 132 Rosalie Rd, Newton Center, MA 02459 Phone: 617-548-0184 Fax: 617-609-7636 |
Elisabeth Boersma, Psy.d. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 10 Langley Rd, Suite 401, Newton Center, MA 02459 Phone: 617-690-9322 |
Green Birches, Llc Dba Lucy Noyes, Ma, Lmhc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 53 Langley Rd, Suite 350, Newton Center, MA 02459 Phone: 617-543-8700 |
Beacon Counseling Inc Psychologist Medicare: Not Enrolled in Medicare Practice Location: 126 Parker St, Newton Center, MA 02459 Phone: 617-244-5594 Fax: 617-244-1272 |
Brent L. Levinson, Ph.d. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 147 Cypress St, Newton Center, MA 02459 Phone: 617-691-7229 |
News Archive
NanoPowers announces closing of CHF 5 million series A financing
NanoPowers SA, a medical device company that leverages its unique artificial muscle technology to restore or improve muscle function, today announced the closing of a CHF 5 million ($4.5 million) series A financing. The financing round was led by Novartis Venture Funds. Also participating in the financing were Initiative Capital Romandie and Gran Plasa SA.
Parents complain that pediatricians, wary of COVID, shift sick kids to urgent care
A mom of eight boys, Kim Gudgeon was at her wits' end when she called her family doctor in suburban Chicago to schedule a sick visit for increasingly fussy, 1-year-old Bryce.
Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011
Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.
Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
Elite suppressors of HIV to change how scientists monitor spread of disease
Scientists at Johns Hopkins have found that 1 percent to 2 percent of those infected with HIV in Baltimore apparently suppress the virus to nearly undetectable levels on their own, confounding public health efforts to accurately monitor the pandemic's spread, now in its 20th year.
› Verified 4 days ago